Breast cancer metastatic

• Tucatinib and trastuzumab in HER3-mutant and HER2-not amplified metastatic breast cancer Pending
  2024-519624-24-00 4 "HER3-mutant and HER2-not amplified metastatic breast cancer"
• LuMIERE: A Phase 1/2, Multicenter, Open label, Non randomized Study to Investigate Safety and Tolerability, Pharmacokinetics, Dosimetry, and … Recruiting
  2023-508995-12-01 4 2025-12-24 "Recurrent or metastatic non-small cell lung cancer (NSCLC)"
• To compare the Safety and activity of GDC-4198 Alone and in Combination with Giredestrant against Abemaciclib and Giredestrant in Participan … Recruiting
  2025-521128-31-00 9 2025-12-18 "Locally Advanced or Metastatic Estrogen Receptor-Positive, h"
• A Study to Learn About the Study Medicine Called PF-07248144 in Combination with Fulvestrant in People with HR-positive, HER2-negative Advan … Recruiting
  2025-520566-22-00 5 2025-11-10 "Hormone Receptor-Positive, HER2-Negative Advanced/Metastatic"
• zAvatar test-guided therapeutic decision vs standard of care, in relapsed ovarian cancer and in metastatic breast cancer - A multicentric ra … Recruiting
  2023-509598-22-01 6 2025-05-13 "Oncology - Breast cancer"
• First -in-Human Study of DS-3939a in Subjects with Advanced Solid Tumors Recruiting
  2023-507937-14-00 7 2025-03-25 "Metastatic Solid Tumor"
• Phase II study evaluating the addition of elacestrant, an oral selective estrogen receptor degrader (SERD), to standard-of-care olaparib in … Recruiting
  2023-504925-38-00 4 2024-12-10 "patients with hormone receptor (HR)-positive, HER2-negative "
• A Phase 3, randomized, open-label, multicenter, controlled study to evaluate the efficacy and safety of zanidatamab in combination with phys … Recruiting
  2023-508960-31-00 5 2024-12-03 "Metastatic HER2-positive breast cancer"
• Basket study for oligo-metastatic breast cancer - ANISE Recruiting
  2023-505039-11-00 4 2024-05-02 "breast cancer, HER2-positive, oligometastatic disease"
• A Modular Open-Label, Multi-Centre Phase 1/2 Dose-Finding, Optimisation, and Expansion Study to Evaluate the Safety,Tolerability, Pharmacoki … Recruiting
  2023-507738-26-00 9 2024-03-20 "Breast Cancer"
• A Master rollover study to provide continued access to, and assess, long term safety of the study drugs. Recruiting
  2023-506330-73-00 5 2024-03-13 "Advanced (unresectable or metastatic) human epidermal growth"
• DS-1103a Combination Therapy First-in-human (FIH) Study Recruiting
  2023-503965-48-00 1 2024-01-11 "Advanced (unresectable or metastatic) human epidermal growth"
• A Study Evaluating the Efficacy and Safety of Inavolisib Plus Phesgo (pertuzumab, trastuzumab, and rHuPH20 injection for SC use) versus plac … Recruiting
  2022-502046-28-00 5 2023-12-22 "HER2-Positive, PIK3CA Mutated, Locally Advanced or Metastati"
• Tucatinib in combination with Oral Etoposide (VP16) and Trastuzumab in Patients with metastatic HER2+ Breast cancer (TUC-TOC) Recruiting
  2022-500743-20-00 4 2023-12-19 "Metastatic HER2+ Breast cancer"
• Measuring Oncological Value of Exercise and Statin (MOVES) Recruiting
  2024-515109-24-00 5 2023-03-31 "Metastatic breast, ovarian, prostate and kidney cancer"
• Study of Zelenectide Pevedotin in Participants with Advanced Breast Cancer Recruitment ended
  2024-517868-33-00 4 2025-06-12 "NECTIN4 Amplified Advanced Breast Cancer"
• A Phase I/II, open-label, multi-center trial of [177Lu]Lu-NeoB in combination with capecitabine in adult patients with gastrin releasing pep … Recruitment ended
  2023-506717-21-00 9 2024-10-02 "Breast Cancer"
• A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Versus Alpelisib Plus Fulvestrant in Patients with Hormone Recepto … Recruitment ended
  2022-502322-41-00 5 2023-09-12 "Metastatic breast cancer"
• A Phase 1b/2 Study of PF-07220060 in Combination with PF-07104091 Plus Endocrine Therapy in Participants with BC and other Advanced Solid Tu … Recruitment ended
  2023-509504-15-00 4 2023-03-20 "HR-positive HER2-negative metastatic/advanced BC"
• A Phase 1/2a study of PF-07220060 in Participants with Advanced Solid Tumors Recruitment ended
  2024-512120-11-00 7 2022-08-31 "Part 2A, 2B, 2C & 2E HR-positive /HER2-negative breast cance"
• A post-trial access roll-over study to allow access to ribociclib (LEE011) for patients who are on ribociclib treatment in Novartis-sponsore … Recruitment ended
  2024-514891-41-00 6 2022-07-19 "HR+, HER2- advanced or metastatic breast cancer"
• Testing a new targeted therapy trastuzumab deruxtecan (DS-8201a) against ado-trastuzumab emtansine (T-DM1) for patients with advanced stage … Recruitment ended
  2024-511204-16-00 5 2019-01-23 "Metastatic breast cancer"
• Impact of 18F-FES TEP on therapeutical management in patients with metastatic breast cancer, ER positive and HER2 negative, in relapse after … Ended
  2024-517400-11-00 6 2024-10-24 "Patients with metastatic breast cancer initially presenting "
• Phase 2 Study of BB-1701 in HER2 positive or HER2-low metastatic breast cancer Ended
  2023-506866-30-00 4 2024-08-19 "HER2 positive or HER2-low metastatic breast cancer"

Showing 1–24 of 28 trials